These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 32661752)

  • 21. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of micropulse laser in patients with diabetic macular edema at the Department of Ophthalmology, Faculty Hospital Hradec Králové.
    Veselá Š; Hejsek L; Stepanov A; Dusová J; Marak J; Jirásková N; Studnička J
    Cesk Slov Oftalmol; 2018; 74(2):53-58. PubMed ID: 30441950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.
    Lang GE; Liakopoulos S; Vögeler J; Weiß C; Spital G; Gamulescu MA; Lohmann C; Wiedemann P
    Acta Ophthalmol; 2018 May; 96(3):e377-e385. PubMed ID: 29090846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
    Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
    Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Outcome of Photobiomodulation for Diabetic Macular Edema: A Case Report.
    Ahadi M; Ebrahimi A; Ramin S
    Photobiomodul Photomed Laser Surg; 2022 Nov; 40(11):742-746. PubMed ID: 36395083
    [No Abstract]   [Full Text] [Related]  

  • 27. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema.
    Mirshahi A; Shenazandi H; Lashay A; Faghihi H; Alimahmoudi A; Dianat S
    Retina; 2010 Feb; 30(2):254-9. PubMed ID: 20057344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes.
    Payne JF; Wykoff CC; Clark WL; Bruce BB; Boyer DS; Brown DM;
    Ophthalmology; 2017 Jan; 124(1):74-81. PubMed ID: 27836430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.
    Augustin AJ; Kuppermann BD; Lanzetta P; Loewenstein A; Li XY; Cui H; Hashad Y; Whitcup SM;
    BMC Ophthalmol; 2015 Oct; 15():150. PubMed ID: 26519345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study).
    Heng LZ; Sivaprasad S; Crosby-Nwaobi R; Saihan Z; Karampelas M; Bunce C; Peto T; Hykin PG
    Br J Ophthalmol; 2016 Jun; 100(6):802-7. PubMed ID: 26472406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.
    Do DV; Schmidt-Erfurth U; Gonzalez VH; Gordon CM; Tolentino M; Berliner AJ; Vitti R; Rückert R; Sandbrink R; Stein D; Yang K; Beckmann K; Heier JS
    Ophthalmology; 2011 Sep; 118(9):1819-26. PubMed ID: 21546089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
    Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
    Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Photobiomodulation Mitigates Diabetes-Induced Retinopathy by Direct and Indirect Mechanisms: Evidence from Intervention Studies in Pigmented Mice.
    Saliba A; Du Y; Liu H; Patel S; Roberts R; Berkowitz BA; Kern TS
    PLoS One; 2015; 10(10):e0139003. PubMed ID: 26426815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. INTEGRITY OF OUTER RETINAL LAYERS AFTER RESOLUTION OF CENTRAL INVOLVED DIABETIC MACULAR EDEMA.
    Muftuoglu IK; Mendoza N; Gaber R; Alam M; You Q; Freeman WR
    Retina; 2017 Nov; 37(11):2015-2024. PubMed ID: 28092342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aflibercept and navigated versus conventional laser in diabetic macular oedema: a 12-month randomized clinical trial.
    Blindbaek SL; Peto T; Grauslund J
    Acta Ophthalmol; 2020 Jun; 98(4):347-352. PubMed ID: 31602811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
    Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alterations in retinal arteriolar microvascular structure associate with higher treatment burden in patients with diabetic macular oedema: results from a 12-month prospective clinical trial.
    Blindbaek SL; Peto T; Grauslund J
    Acta Ophthalmol; 2020 Jun; 98(4):353-359. PubMed ID: 31654501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.
    Wykoff CC; Ou WC; Khurana RN; Brown DM; Lloyd Clark W; Boyer DS;
    Br J Ophthalmol; 2018 May; 102(5):631-636. PubMed ID: 28814412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.